Rio Tinto (RIO) shares were down over 3% in Wednesday trading after RBC Capital Markets downgraded the stock to underperform from sector perform.
Trading volume stood at more than 1.9 million shares, compared with a daily average of close to 2.8 million.
Price: $108.09, Change: $-3.59, Percent Change: -3.21%
Nu Holdings (NU) shares fall 4% in Wednesday trading after Susquehanna downgraded the stock to neutral from positive and lowered its price target to $13 from $18.Trading volume stood at more than 80.6 million shares against daily average of about 52.5 million.Price: $11.46, Change: $-0.47, Percent Change: -3.94%
Cognyte Software (CGNT) shares sank 22% after the company reported a year-over-year slump in fiscal Q1 non-GAAP earnings on Wednesday, taking the shine out of sales growth.More than 2.26 million shares of the company traded intraday compared with a daily average of about 579,000.CID HoldCo (DAIC), which does business as Dot Ai, is exploring a range of strategic alternatives, including, but not limited to, a sale of the company, a merger or other business combination, a strategic partnership or joint venture, licensing arrangements, or a liquidation and dissolution.Shares slumped 17% as intraday trading volume increased to over 351,000 from a daily average of about 93,000.Susquehanna adjusted its price target for Global Payments (GPN) shares to $111 from $119 while maintaining its positive rating.Shares of Global Payments traded 8% lower, with intraday trading volume rising to over 7.68 million from a daily average of roughly 3.32 million.Price: $68.01, Change: $-6.02, Percent Change: -8.13%
Novartis (NVS) said Wednesday new Cosentyx data from a late-stage trial in polymyalgia rheumatica showed a statistically significant, clinically meaningful difference in sustained remission rates against placebo and significant steroid sparing.The effect of Cosentyx treatment was sustained through week 52, the company said, adding that the trial met all primary and secondary endpoints, and no new safety signals were identified.Novartis said it has submitted Cosentyx for regulatory review in the US, EU, and Japan, with other filings expected to follow throughout 2026, it added.Separately, Novartis Canada said it has reached an agreement with the pan-Canadian Pharmaceutical Alliance for the public reimbursement of Scemblix for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.Price: $143.53, Change: $+0.05, Percent Change: +0.03%